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Harnessing the CRISPR/Cas9 system to
disrupt latent HIV-1 provirus
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Even though highly active anti-retroviral therapy is able to keep HIV-1 replication under control, the virus
can lie in a dormant state within the host genome, known as a latent reservoir, and poses a threat to
re-emerge at any time. However, novel technologies aimed at disrupting HIV-1 provirus may be capable of
eradicating viral genomes from infected individuals. In this study, we showed the potential of the CRISPR/
Cas9 system to edit the HIV-1 genome and block its expression. When LTR-targeting CRISPR/Cas9
components were transfected into HIV-1 LTR expression-dormant and -inducible T cells, a significant loss
of LTR-driven expression was observed after stimulation. Sequence analysis confirmed that this CRISPR/
Cas9 system efficiently cleaved andmutated LTR target sites. More importantly, this systemwas also able to
remove internal viral genes from the host cell chromosome. Our results suggest that the CRISPR/Cas9
system may be a useful tool for curing HIV-1 infection.
I
ntegration of reverse transcribed viral DNA into the host cell genome is an essential step during the HIV-1 life
cycle1. The integrated retroviral DNA is termed a provirus, which serves as the fundamental source of viral
protein production. HIV-1 gene expression is regulated by LTR promoter and enhancer activities, where
cellular transcription factors such as NF-kB, SP-1 and TBP bind to promote RNA polymerase II processivity.
Subsequently, Tat protein is expressed from early double-spliced transcripts and binds to the trans activation
response (TAR) region of HIV-1 RNA for its efficient elongation2.
Latent infection occurs when the HIV-1 provirus becomes transcriptionally inactive, resulting in a latent
reservoir that has become the main obstacle in preventing viral eradication from HIV-1 infected individuals.
However, the mechanisms of viral silencing and reactivation remain incompletely understood3. Previous studies
have suggested that the position of the integration site strongly influences viral gene expression andmay be one of
the determinants of HIV-1 latency4. While highly active anti-retroviral therapy (HARRT) has dramatically
decreased mortality from HIV-1 infection, there is currently no effective strategy to target the latent form of
HIV-1 proviruses5.
Over the last decade, novel genome-editing methods that utilize artificial nucleases such as zinc finger
nucleases (ZFNs)6 and transcription activator like-effector nucleases (TALENs)7 have been developed. These
molecularly engineered nucleases recognize and cleave specific nucleotide sequences in target genomes for
digestion, resulting in various mutations such as substitutions, deletions and insertions induced by host DNA
repair machinery. These technologies have enabled the production of genome-manipulated animals in a wide
range of species such as Drosophila8, Zebrafish9 and Rat10. However, ZFNs or TALENs remain somewhat difficult
and time-consuming to design, develop, and empirically test in a cellular context11. Recently, a third genome-
editing method was developed based on clustered regularly interspaced short palindromic repeat (CRISPR)
systems. CRISPR systems were originally identified in bacteria and archaea12 as part of an adaptive immune
system, dependent on a complex consisting of CRISPR RNAs (crRNAs) and CRISPR-associated (Cas) proteins to
degrade complimentary sequences of invading viral and plasmid DNA. Mali et al. created a novel version of the
genome-editing tool applicable to mammalian cells, termed the CRISPR/Cas9 system, which is based on mod-
ifications of the Streptococcus pyogenes type II CRISPR system in crRNA fused to trans-encoded tracrRNA13. This
CRISPR/Cas9 system is composed of guide RNA (gRNA) and a human codon-optimized Cas9 nuclease that
forms an RNA-protein complex to digest unique target sequences matching those of gRNA. The CRISPR/Cas9
system can be utilized by simple transfection of designed gRNA and a humanized Cas9 (hCas9) expression
plasmid into target mammalian cells, making it a promising tool for various applications.
In this study, we tested the ability of the CRISPR/Cas9 system to suppress HIV-1 expression by editing HIV-1
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inhibited LTR-driven expression under the control of Tat. This LTR-
targeted CRISPR/Cas9 system can also excise provirus from the cel-
lular genome.
Results
LTR-specific editing by CRISPR/Cas9 components disrupts HIV-
1 expression machinery.We designed a gRNA expression vector to
target HIV-1 LTR under the control of the human U6 polymerase III
promoter. U6 transcription of gRNA is initiated with guanine and
requires the protospacer-adjacent motif (PAM)–NGG followed by a
20-base pair (bp) target sequence13. Accordingly, two gRNA-
expressing plasmids were generated for targets 5 and 6 (T5 and
T6), located in the TAR sequence of the R region and NF-kB
binding sequence in the U3 region, respectively (Fig. 1 A), as
described in methods. To test the genome editing activity of the
CRISPR/Cas9 system, we used HIV-1 provirus-integrated human
cells generated by an LTIG HIV vector, which expresses Tat and
GFP proteins under the control of an LTR promoter, thus
mimicking authentic HIV-1 gene expression4. To assess the impact
of the CRISPR/Cas9 system targeting HIV-1 LTR, 293 T and HeLa
cells were infected with an LTIG vector pseudotyped with VSV-G
envelope protein. Then, the LTIG vector-infected cells were co-
transfected with a T5 or T6 gRNA expression plasmid together
with an hCas9 expression plasmid. Five days after transfection
(TF), the mean fluorescence intensity (MFI) of GFP expression
and percentage of GFP positive cells were analyzed by flow
cytometry. In the 293 T cells, a clear reduction of MFI and GFP
positive cells were observed by the CRISPR/Cas9 components
(Fig. 1B and C). T5, the TAR-targeting gRNA, was more effective
than T6 and reduced the average percentage of GFP positive cells
from 45.6% to 20.0% (p5 0.0003) (Fig. 1C). Only amodest decline of
GFP positive cells was observed in HeLa cells, while the MFI
reduction was more drastic than that in 293 T cells (Fig. 1C),
probably due to a lower TF efficiency of CRISPR components and
a lower level of GFP expression in HeLa cells than in 293 T cells.
These results suggested that the HIV-1 LTR targeting CRISPR/Cas9
system blocked HIV-1 gene expression from provirus LTR. Because
the most efficient inhibition was obtained by T5 in both 293 T and
HeLa cells, T5 was used for the further experiments.
To enhance the inhibition activity of the CRISPR/Cas9 system, we
developed a protocol to transfect CRISPR components multiple
times. 293 T cells were repeatedly co-transfected with T5 gRNA or
gRNA empty and hCas9 plasmids, and flow cytometry analysis was
performed five days after TF. As expected, the percentage of GFP
positive cells was further reduced after multiple rounds of TF
(Fig. 1D). Triple TF resulted in a significant decrease in the mean
percentage of GFP positive cells from 40.8% to 2.1% (p5 0.0001) was
observed. LTR fragments were then isolated from these cells using
the primer set as indicated in Fig. 1A and cloned into a plasmid.
Sequence analysis of the TAR region of plasmid DNA clones showed
that 18 out of 22 HIV DNA clones contained various mutations,
between 1 and 31-bp deletions from the end of the putative cleavage
site (Fig. 2A). Two clones had a combination of deletion and inser-
tionmutations (Fig. 2B). These mutation patterns are often observed
as a result of DNA repair in the non-homologous end joining (NHEJ)
pathway and are typical after genome editing14, strongly suggesting
that this T5 CRISPR/Cas9 component generated double-strand (ds)
DNA breaks specifically at the HIV-1 TAR target site, and were
repaired through the NHEJ pathway. These results clearly showed
that the T5 CRISPR/Cas9 system efficiently produced mutations in
the TAR region of proviral DNA.
CRISPR/Cas9 system can target the latent form ofHIV-1 provirus
in Jurkat cell. Because the putative latently infected cells are CD41 T
cells, we next tested the genome editing potential of the CRISPR/
Cas9 system in these cells. To test this, we generated two Jurkat clone
cell lines, c5 and c19, that mimic HIV latency. These cell clones were
isolated by limiting-dilution from cell populations that only
expressed GFP after induction by either TNF-a or a combination
of 5-Aza-dC/TSA. Both c5 and c19 were co-transfected with a T5 or
gRNA empty vector and hCas9 expression plasmid. Four days later,
cells were treated with TNF-a or a combination of 5-Aza-dC/TSA.
The mean percentage of GFP positive cells after TNF-a induction
was 92.56% and 98.48% after TF with gRNA empty vector in c5 and
c19 cells, respectively. In contrast, the mean percentages of GFP
positive cells were 68.78% in c5 and 66.95% in c19 cells,
transfected with T5 gRNA (Fig. 3A and B). A similar reduction in
GFP expression was observed in c5 and c19 cells transfected with the
T5CRISPR/Cas9 system after 5-Aza-dC/TSA treatment (Fig. 3A and
B). These data suggest that the T5 CRISPR/Cas9 system produced
cell populations, which were resistant to TNF-a and 5-Aza-dC/TSA
stimulation.
To increase the efficiency of the T5 CRISPR/Cas9 system, we
performed multiple TF of T5 and hCas9 expression plasmids. This
approach significantly reduced the re-activation of latent provirus.
As shown in Fig. 3C for c19, the percentage of re-activated latently
infected cells was reduced from 97.8% to 35.5% after three rounds of
TF (Fig. 3C, p5 0.00002). These results clearly demonstrated that the
T5 CRISPR/Cas9 system was able to prevent the re-activation of
latently integrated provirus in T cells.
CRISPR/Cas9 system removes HIV-1 internal genes. Retrovirus
proviral DNA contains duplicate LTR regions on both ends of the
integrated viral genome, meaning that the CRISPR/Cas9 systemmay
simultaneously cleave both LTRs and remove an internal region of
integrated proviral DNA from the host cell genome. To examine this
possibility, we used cells transduced with an alternative HIV-1
vector, missing the U3 region of the LTR and possessing an
internal elongation factor-1 (EF) promoter cassette for GFP
expression (Fig. 4A). Because GFP expression is driven by an
independent EF-promoter, it should be unaffected by the genome-
editing system targeting the LTR region of integrated proviral DNA.
Therefore, the GFP negative cell populations may be the result of
proviral excision. Moreover, since this HIV vector lacks the NF-kB
binding site in the U3 region, these cells should be resistant to T6 and
not T5-mediated targeting. As expected, only T5 CRISPR/Cas9
components clearly reduced the cell populations expressing GFP
(Fig. 4 A, p 5 0.0014). Double TF of these components resulted in
a further decrease of average of GFP positive cells from 60.44% to
50.45% (p 5 0.0010).
Next, we performed quantitative PCR (qPCR) analysis using c19
Jurkat cells that harbored latently integrated HIV-1 proviral DNA,
the LTIG vector. As shown in Fig. 3, the T5 CRISPR/Cas9 system
significantly reduced LTR-driven GFP expression. We reasoned that
if the inhibition is purely a result of LTR mutations, then, the EGFP
DNA copy number in the host cell genome should be unchanged
following T5 CRISPR/Cas9 treatment. Alternatively, if the reduction
of GFP expression is partially attributed to the excision of integrated
viral DNA, the amount of EGFP DNA will be reduced after T5
CRISPR/Cas9 treatment. For this assay, the c19 cells from Fig. 3C
were used. The result of qPCR analysis clearly showed that the rela-
tive amount of EGFP DNA was decreased by the T5 but not gRNA
empty CRISPR/Cas9 treatment (Fig. 4B). On average, 31.8% of the
provirus was excised from the host cell genome after CRISPR/Cas9
components were transfected three times. To obtain direct evidence
of the provirus-excision effect by CRISPR, PCR analysis using the
host cell genome-specific primers, flanking the proviral integration
site, was performed. After determining the integration sites of c19,
chromosome 16 in latent LTIG-transduced Jurkat cells (Fig. 4D bot-
tom), we designed a primer set specific for both sequences adjacent to
the integration site of c19 provirus. The excision of provirus is pre-
dicted to leave a footprint of one LTR and the PCRwe performedwas
www.nature.com/scientificreports
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Figure 1 | Suppression of HIV-1 gene expression by the CRISPR/Cas9 system targeting HIV-1 LTR. (A) Schematic of provirus derived from LTIG
vector and the LTR. Two target sites of CRISPR/Cas9 were indicated at the bottom of the LTR. (B and C) GFP expression after CRISPR/Cas9 treatment.
293 T andHeLa cells were infected with LTIG vector pseudotyped with VSV-G protein. One week after infection, the cells were co-transfected with gRNA
expression vector and hCas9 expression vector. The level of GFP expression was analyzed by flow cytometry at 5 days after TF. (B) Representative
histograms are shown. (C) GFP positive percentages (top, n 5 3), andMFIs (bottom, n 5 3) are shown. (D) Percentage of GFP positive 293 T cells after
multiple TF with the CRISPR/Cas9 system. Flowchart of the experiment is depicted on the left side. The percentage of GFP positive cells resulting from
single, double and triple TF is shown on the right side. The error bars in C and D show standard deviations (n 5 3).
www.nature.com/scientificreports
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able to detect the apparent footprint as an additional 1,067 bp frag-
ment only in the T5 CRISPR/Cas9-transfected cells (Fig. 4C).
Furthermore, sequence analysis of this PCR product confirmed that
excision of provirus resulted in one LTR footprint with a variety of
mutations from the cleavage site (Fig. 4D). These results clearly
demonstrate that the CRISPR/Cas9 system targeting HIV-1 LTR
has the potential to excise latent form of HIV-1 proviral DNA from
the host cell chromosome.
Discussion
In this study, we successfully disrupted the expression of HIV-1
provirus utilizing the CRISPR/Cas9 system (Fig. 1). Importantly, this
disruption not only restricted transcriptionally active provirus, it also
blocked the expression of latently integrated provirus (Fig. 3). Cas9
proteins are predicted to contain RuvC and HNH motifs15, which
possess autonomous ssDNA cleavage activity. Interestingly, mutants
lacking one of themotifs become nicking endonucleases16. It is plaus-
ible that the independent nicking activity of each domain may
enhance efficient access to the heterochromatin state of latently inte-
grated provirus. Another possibility is that Cas9 has a highly efficient
target surveillance system similar to what has been previously
reported for the Cas3 system17.
T6 gRNA that targeted the NF-kB binding site, also strongly sup-
pressed the LTR promoter activity (Fig. 1). However, the effect was
weaker than that of T5 gRNA. In this study we used an LTIG vector
modified from the LTR of HIV-1 strain NL4-3 that possesses two
adjacent NF-kB binding sites18. The T6 target site is at the end of the
59 NF-kB binding site, meaning that mutations may not completely
render transcription inactive since the 39 NF-kB binding site may
remain functional. On the other hand, T5 gRNA that targeted TAR,
is profoundly effective in disrupting HIV-1 gene expression. The
putative cleavage site was positioned at the neck of the stem loop
region of TAR, which is critical for Cyclin T1-Tat-TAR ternary com-
plex formation19. Therefore, the TAR sequencemay be one of the best
targets for blocking HIV-1 provirus expression. Target specificity of
the CRISPR/Cas system is very high and a single mutation can dis-
rupt targeting20, meaning that some provirus may escape from this
genome-editing machinery if mutations arise in target sequences.
However, given that the TAR region is relatively conserved and there
is little variation among HIV-1 subtypes21, it could still be an appro-
priate target for the elimination of latently infected provirus.
Perhaps the most important finding in this study is that we could
excise provirus from the host genome of HIV-1 infected cells, which
may provide a ray of hope to eradicate HIV-1 from infected indivi-
duals. However, there are numerous hurdles that must be cleared
before utilizing genome editing for HIV-1 eradication therapies such
as gene therapy. First, the efficiency of genome-editing and/or proviral
excision should be quantified in HIV infected primary cells, including
latently infected CD41 quiescent T cells. Second, an efficient delivery
system must be developed. Fortunately, the CRISPR/Cas9 system has
the advantage in size compared with TALENs22. Thus, the CRISPR
system has the potential to be delivered by lentivirus vectors, whereas
TALENs do not because of their large size and repeat sequences23. The
final hurdle concerns possible off-target effects, which are pertinent
concerns for all genome-editing strategies that may lead to nonspecific
gene modification events. If Cas9 has off-target effects, then removal
of the off-target activity may be the best approach before utilizing
CRISPR/Cas system for anti-HIV treatment.
Figure 2 | Sequencing analysis of the CRISPR/Cas9-target site. DNA sequence of the TAR region of LTR is indicated. Twenty-two sequences were
obtained from LTIG-infected 293 T cells which were transfected three times with T5 gRNA. The WT reference sequence is shown on the top. The target
sequence of T5 is indicated in orange. The putative cleavage site is indicated with an arrowhead. (A) TAR sequence with deletions. Eighteen out of 22
clones were deletion mutants. (B) TAR sequence with both deletions and insertions. Two out of 22 clones were mutants consisting of insertion and
deletion. Red and blue colors indicate insertion and unanticipated mutation, respectively.
www.nature.com/scientificreports
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Methods
gRNA expression plasmid. gRNA expression plasmids were constructed according
to manufacturer’s protocol. Briefly, to make a 100 bp dsDNA insert fragment
containing the target sequence (20 bp) and PAM sequence, a set of oligonucleotides
was used and the fragment was generated by using Phusion polymerase (NEB). The
dsDNA fragment was purified and inserted into the AflII site of a gRNA_cloning
vector (addgene) with the Gibson assembly system (NEB). Two sets of
oligonucleotides targeting 5 and 6 are listed as follows: HE388 (TTTCTTGGCTTTA
TATATCTTGTGGAAAGGACGAAACACCGttagaccagatctgagcct) and HE389
(GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACaggctcagatctggt
ctaaC); and HE384 (TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACA
CCGctacaagggactttccgct) and HE385 (GACTAGCCTTATTTTAACTTGCTATTT
CTAGCTCTAAAACagcggaaagtcccttgtagC), respectively. Lower case letters indicate
the target sequence. These 60 nt oligonucleotide sets annealed to each other over a
20 nt complementary sequence at the 39 ends.
Virus. Viruses were prepared as described previously24. Briefly, 293 T cells were
transfected and the culture supernatants were filtrated 48 hours post TF. To prepare
Figure 3 | Suppression of proviral re-activation in T cells by the CRISPR/Cas9 system. Jurkat cell lines latently-transduced with LTIG vector were used.
These cell lines were co-transfected with gRNA expression vector and hCas9 expression vector. The cells were treated with TNF-a or the combination of 5-
Aza-dC and TSA 4 days after TF. (A and B) The level of GFP expression after 48 hours of TNF-a stimulation and 24 hours 5-Aza-dC and TSA
stimulation. Representative histograms are shown in A. The positive percentage of GFP is shown in B (n 5 3). (C) Multiple TF of T5 or gRNA empty
vector and hCas9 expression plasmid. Solid lines with squares and circles indicate c19 and c5 co-transfected with gRNA empty and hCas9 expression
vector, respectively. Dotted lines with x and triangles indicate c19 and c5 co-transfected with T5 and hCas9 expression vector, respectively. The error bars
in B and C show standard deviations (n 5 3).
www.nature.com/scientificreports
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VSV-G pseudotyped LTIG vector, pEV731, kindly provided by Dr. Eric Verdin25,
pMD. G, pMDLg/pRRE and pRSV Rev (helper plasmids) were co-transfected. To
prepare VSV-G pseudotyped EG-PRE vector, pCS-CDF-EG-PRE vector and the
same helper plasmids were co-transfected as described previously26.
Cell culture. 293 T and HeLa cells were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) containing 10% fetal calf serum (FCS), 100 U/ml penicillin and
100 g/ml streptomycin. Jurkat cells were maintained in RPMI 1640 medium
containing 10% FCS, 100 U/ml penicillin and 100 g/ml streptomycin.
Figure 4 | Excision of HIV-1 provirus from host cell genome with CRISPR/Cas9. (A) Excision of lentivirus vector with the CRISPR/Cas9 system. 293 T
cells, transduced with lentivirus vector containing an EF promoter derived-EGFP expressing cassette, were treated with the CRISPR/Cas9 system. A
schematic of the lentivirus vector used in this assay is shown on top. The percentage of GFP positive cells after single or double TF of CRISPR/Cas9
components is shown on the bottom (n 5 3). (B) Excision of LTIG provirus with CRISPR/Cas9 system. The genomic DNA was extracted from the
samples derived fromFig. 3C and qPCRwas performed (n5 3). The relative amount of EGFPDNA is shown. (C) PCR amplification ofHIV-1 provirus. A
primer set was designed for the host cell genome sequence flanking the proviral integration site in c19. The schematic of PCR products indicating genomic
sequences, full-length provirus and one LTR footprint resulting from proviral excision are shown on the right side. (D) DNA sequence of one LTR
footprint resulted from proviral excision. TAR sequence ofWT LTR is shown on the top in bold. Target sequence of T5 gRNA is indicated in orange. The
putative cleavage site is indicated with an arrowhead. LTR sequences from five clones are shown in themiddle. Deletions are indicated by dashes. Insertion
is shown in Red. The 5-bp direct repeat in host DNA, flanking LTR ends, is shown in green. The host cell genome sequence is indicated on the bottom.
www.nature.com/scientificreports
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TF and flow cytometry. 293 T cells were transfected by the calcium phosphate
method24. HeLa cells were transfected by Lipofectamine2000 (invitrogen) according
to the manufacturer’s protocol. Jurkat clone cells were transfected by NEON
transfection system (life technology). For TF of CRISPR/Cas9 system, 1 mg of hCas9
expression vector and 1 mg of gRNA expression vector was used. The level of GFP
expression was analyzed 5 days after TF. Cells were suspended in phosphate-buffered
saline (PBS) containing 1% formamide. Flow cytometry was performed with a
FACScCalibur (BD Biosciences), and data were analyzed using CellQuest software
(BD Biosciences).
Establishment of latent form of LTIG-transduced Jurkat cells. Jurkat cells were
infected with LTIG pseudotyped vector at MOI 0.5 and cultured for one weak. After
treatment with 10 ng/ml TNF-a for 24 hours, GFP positive cells were sorted by
FACSAria (BD) and cultured for another one month to relax the GFP expression.
Then, GFP negative cells were sorted four times, and the cells were cloned by limiting-
dilution. After expanding, clone cells were treated with 10 ng/ml of TNF-a (R&D
systems) or a combination of 1 mg/ml 5-Aza-dC (SIGMA-ALDRICH) and 1 mMTSA
(SIGMA-ALDRICH), and screened for the potential to be reactivated after
stimulation, by flow cytometry.
Integration-site analysis of latently integrated LTIG provirus. Genomic DNA
extracted from Jurkat cell clones were digested with a combination of BamHI and
BclI, or NcoI and BspHI and re-ligated by T4 ligase. The ligation products were EtOH
precipitated and used as the template for inverse PCR. For this PCR, LA taq
(TAKARA) were used according to the manufacturer’s protocol. Primer sets used for
the inverse PCR were HE410 (CTCCTCGCCCTTGCTCACCA) and M667
(GGCTAACTAGGGAACCCACTGC). The PCR products were cloned into pGEM-
T (Promega) vector and sequenced using M13 primers. Primer set, HE433
(AGCACATCACACTCCTCTG) and HE435 (AGACATGAGCCACTATGTCT)
were used for PCR amplification of integrated provirus in c19.
Quantitative analysis of HIV DNA. The amount of EGFP DNA was quantified by
real-time PCR as previously described27,28.
Statistical analysis. All data were expressed as mean 6 standard deviations (S.D.).
The student’s t test was used to indicate the differences between groups. P values are
shown in each figure.
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